Fundz

GSK acquires RAPT Therapeutics for $2.2B

PUBLIC · GSKMar 08, 2026

Acquiring Company

GSK plc

Acquired Company

RAPT Therapeutics

South San FranciscoManufacturingBiotechnologyHealth CarePharmaceuticalBiotechnology

Description

On March 3, 2026, GSK completed its acquisition of RAPT Therapeutics for $2.2 billion. This strategic move enhances GSK's pipeline with a late-stage food allergy antibody. Following shortly after, GSK also acquired 35Pharma for $950 million, targeting the growing pulmonary hypertension market. These acquisitions are part of GSK's roadmap to achieve £40 billion in annual revenue by 2031.

Quick answer

GSK plc is acquiring RAPT Therapeutics for $2.2 billion, announced March 8, 2026.

How much did GSK plc pay for RAPT Therapeutics?
The reported deal value is $2.2 billion.
What does GSK plc do?
GSK plc is a global healthcare company that researches and develops innovative pharmaceutical products, including vaccines.
Where are GSK plc and RAPT Therapeutics based?
RAPT Therapeutics is based in South San Francisco, California, United States.
Who are the decision-makers at GSK plc?
Fundz holds 4 contacts at GSK plc. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Other recent acquisitions in Pharmaceutical and Manufacturing

Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.

Who to call at GSK plc, and when

When GSK plc changes hands, the new owners review vendors, systems and leadership. That is when the door opens.

  • An alert the day GSK plc raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at GSK plc, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at GSK plc. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

GSK plc

Location

79 New Oxford Street

About

GSK plc is a global healthcare company that researches and develops innovative pharmaceutical products, including vaccines. The company is dedicated to improving the quality of human life by enabling people to do more, feel better, and live longer. GSK focuses on a range of health needs, including respiratory diseases, and has a commitment to develop life-saving medications and preventative treatments.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment GSK plc makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Luke
Likely contact at this company
••••••••@••••••••

See Luke's verified email →

Anshuman
Senior decision-maker at this company
••••••••@••••••••

See Anshuman's verified email →

Vineet
Senior decision-maker at this company
••••••••@••••••••

See Vineet's verified email →

Saurabh
Senior decision-maker at this company
••••••••@••••••••

See Saurabh's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for GSK plc's next move

Learn about Strategic plan

Frequently asked

Who acquired RAPT Therapeutics?

RAPT Therapeutics was acquired by GSK plc. The deal was reported on March 8, 2026. GSK plc is a global healthcare company that researches and develops innovative pharmaceutical products, including vaccines. GSK plc is publicly traded (GSK) and operates in Manufacturing.

When did GSK plc acquire RAPT Therapeutics?

GSK plc's acquisition of RAPT Therapeutics was reported on March 8, 2026. On March 3, 2026, GSK completed its acquisition of RAPT Therapeutics for $2.2 billion. This strategic move enhances GSK's pipeline with a late-stage food allergy antibody. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does RAPT Therapeutics do?

Rapt Therapeutics is a pharmaceutical firm developing novel therapies for patients living with inflammatory and immunologic diseases. It is privately held, operating in Biotechnology, and is based in South San Francisco.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.